Lineage Cell Therapeutics EBIT

The latest EBIT for LCTX is $-16M as of June 2026. That compares with $-20M in the prior-year period — up 19.7% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Lineage Cell Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, LCTX's EBIT moved from $-20M to $-16M — a 19.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lineage Cell Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, LCTX currently prints $-16M for EBIT, while the sector average sits near $23B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Lineage Cell Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-16M for LCTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting LCTX's EBIT ($-16M), review year-over-year change from $-20M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.